Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth.

PloS one - 1 Jan 2018

Bäumer Nicole, Rehkämper Jan, Appel Neele, Terheyden Lisa, Hartmann Wolfgang, Wardelmann Eva, Buchholz Frank, Müller-Tidow Carsten, Berdel Wolfgang E, Bäumer Sebastian

Abstract excerpt

Precision cancer therapy requires on the one hand detailed knowledge about a tumor's driver oncogenes and on the other hand an effective targeted therapy that specifically inhibits these oncogenes. While the determination of genomic landscape of a tumor has reached a very precise level, the respective therapy options are scarce. The application of small inhibitory (si) RNAs is a promising field of investigation....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cetuximab
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to HT29 Cells

Share to Mice, Nude

Share to RNA, Small Interfering

Share to Tumor Stem Cell Assay

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 30001368
DOI: 10.1371/journal.pone.0200163
PMCID: PMC6042707

Genes

EGFR
KRAS
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth.PMID 30001368Read ↗

Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.Semantic proximity Read ↗

Cetuximab-siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib.Semantic proximity Read ↗

Disrupting KRAS-AGO2 interaction: a dual-pronged strategy to sensitize chemo-immunotherapy in KRAS-mutated colorectal cancer.Semantic proximity Read ↗

Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.Semantic proximity Read ↗

Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cellsSemantic proximity Read ↗

Synergistic Approach of Antibody-Photosensitizer Conjugate Independent of KRAS-Mutation and Its Downstream Blockade Pathway in Colorectal Cancer.Semantic proximity Read ↗

Exploring the Potentials of Antibody–siRNA Conjugates in Tumor Cell Gene Silencing without Cationic AssistanceSemantic proximity Read ↗

Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment.Semantic proximity Read ↗

EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach.Semantic proximity Read ↗

Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment.Semantic proximity Read ↗

Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNASemantic proximity Read ↗

Biomembrane-permeable and Ribonuclease-resistant siRNA with enhanced activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.